Page 8 - P4304.1-V108_PS Magazine - Apr 25_Neat
P. 8

This promotional advert was created by Accord Healthcare Ltd and is intended for UK Healthcare Professionals.
                             Varenicline Tablets





                                                      0.5mg & 1mg






                                                                                                                                                        PSUK is pleased to offer a 40% discount

                                                                                                                                                        on Sereflo pMDIs for dispensing practices







                                                                                                                                     Product               NHS List price 1    PSUK discount        Saving

                                                                                                                                     Sereflo pMDI                                 40%                £5.99
                                                                                                                                     25/125mcg                 £14.99

                                                                                                                                     Sereflo pMDI              £19.99             40%                £7.99
                                                                                                                                     25/250mcg

                                                                                                                                    Sereflo pMDI can offer a 25mcg salmeterol with 125 or 250mcg fluticasone
                                                                                                                                    combination more cost-effectively than the market-leading competitors,
                                                                                                                                    Seretide® and Sirdupla® (salmeterol/fluticasone).  Plus, you can take
                                                                                                                                                                              1-3
             •  Initiation pack and maintenance dosing.                                                                             advantage of significant additional savings with the PSUK discount.


                                                          Product Presentation
                                                                                                                                    Sereflo pMDI is indicated for use in adults with asthma 18 years of age and older only. 4,5
              Strength               0.5mg          0.5mg + 1mg       0.5mg + 1mg         1mg               1mg
                                                                                                                                    Sereflo pMDI is indicated in the regular treatment of patients with moderate to severe asthma
              Pack Size               56             25 (11+14)        53 (11+42)          28                56                     where use of a combination product (long-acting β2 agonist and inhaled corticosteroid)
                                                                                                                                    is appropriate:
              Product Format     film-coated tablet  film-coated tablet  film-coated tablet  film-coated tablet  film-coated tablet  - patients not adequately controlled on a lower strength corticosteroid combination product 4,5
                                                                                                                                    or
              Legal Category         POM               POM               POM              POM               POM                     - patients already adequately controlled on an inhaled corticosteroid in a mid or
                                                                                                                                    high strength and a long-acting β2 agonist. 4,5
              Pack Dimensions     48mmx116mm       70mmx134mm        134mmx119mm       48mmx116mm       48mmx116mm
              (HxWxD)               x37mm             x22mm             x22mm            x25mm             x37mm                    Seretide is a trademark of GSK. Sirdupla is a registered trademark of Mylan.
                                                                                                                                    pMDI = pressurised metered dose inhaler.
              Shelf Life           24 months         24 months         24 months        24 months         24 months
              PIP Code              127-5338         127-5361          127-5379          127-5353         127-5346                  Sereflo  Metered Dose Inhaler (salmeterol xinafoate/fluticasone   with caution in patients with severe cardiovascular disorders or heart rhythm abnormalities and in
                                                                                                                                         ®
                                                                                                                                    propionate)                                             patients with diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or with a predisposition to
                                                                                                                                                                                            low levels of serum potassium. Prescribers should also be aware of the risk of adrenal suppression
              EAN Code           5012617003249     5012617003256     5012617003263    5012617003270     5012617003287               Prescribing Information                                 and acute adrenal crisis which may occur in patients on prolonged treatment with high doses of
                                                                                                                                    Please consult the full Summary of Product Characteristics (SmPC) before prescribing
                                                                                                                                    Sereflo 25 microgram (μg) salmeterol xinafoate /125 μg or 250 μg fluticasone propionate per actuation   inhaled corticosteroids. Systemic effects may occur with any inhaled corticosteroid and it is important
                                                                                                                                                                                            therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is reduced to the
              Trade Price¹           £46.40           £23.20            £56.50            £23.20           £46.40                   pressurised inhalation, suspension. For both dose strengths the equivalent delivered dose per   lowest dose at which effective control of asthma is maintained. Visual disturbances may be reported
                                                                                                                                    actuation is 21 μg of salmeterol and the delivered fluticasone propionate is 110 μg, for 125 μg dose
                                                                                                                                    strength and 220 μg, for 250 μg dose strength. INDICATIONS: For use in adults with asthma 18 years   with steroid use. Patients presenting with blurred vision or other visual disturbances should be
                                                                                                                                                                                            considered for referral to an ophthalmologist. Drug Interactions: Concomitant use should be avoided
             1. Accord Proposition Price List February 2025                                                                         of age and older only. Sereflo is indicated in the regular treatment of patients with moderate to severe   with; non-selective and selective β blockers, ritonavir and other potent/moderate CYP3A inhibitors,
                                                                                                                                    asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is
                                                                                                                                    appropriate: patients not adequately controlled on a lower strength corticosteroid combination product   unless potential benefit outweighs the risk. Particular caution is advised in acute severe asthma
                                                                                                                                                                                            as hypokalaemia may be potentiated by concomitant treatment with xanthine derivatives, steroids
                                 Please click or scan the QR codes below to access the SPC.                                         or patients already adequately controlled on an inhaled corticosteroid in a mid or high strength and   and diuretics. See the SmPC for further information on contraindications and precautions.
                                                                                                                                    a long-acting β2 agonist. POSOLOGY AND ADMINISTRATION: Patients should be instructed
                                                                                                                                    in the proper use of their inhaler (see SmPC and patient information leaflet). Recommended   PREGNANCY AND LACTATION: Balance risks against benefits. UNDESIRABLE EFFECTS:
                                                                                                                                    doses in adults 18 years and older - Two inhalations of 25μg salmeterol and 125 μg or 250 μg   Adverse events which have been associated with salmeterol/fluticasone propionate include: Very
                                                         Varenicline Tablets 0.5mg                                                  fluticasone propionate twice daily. A short-term trial of salmeterol and fluticasone propionate may be   common; nasopharyngitis and headache; Common; candidiasis of the mouth and throat, pneumonia,
             Varenicline Tablets 0.5mg  Varenicline Tablets 1mg  & 1mg (initiation pack)                                            considered as initial maintenance therapy in adults with moderate persistent asthma for whom rapid   bronchitis, hypokalaemia, throat irritation, hoarseness/dysphonia, sinusitis, contusions, muscle
                                                                                                                                                                                            cramps, traumatic fractures, arthralgia and myalgia. For other adverse events please consult the full
                                                                                                                                    control of asthma is essential. In these cases, the recommended initial dose is two inhalations of 25
                                                                                                                                    μg salmeterol and 50 μg fluticasone propionate twice daily. Note: Sereflo is not available in a lower   SmPC. MARKETING AUTHORISATION HOLDER & PL NUMBERS: Cipla (EU) Ltd. Dixcart House,
                                                                                                                                    strength product containing salmeterol 25 μg and fluticasone propionate 50 μg. Therefore, when   Addlestone Road, Bourne Business Park, Addlestone, Surrey KT15 2LE. PL 36390/0237 and PL
                                                                                    Adverse events should be reported.              initiating therapy, or when it is appropriate to titrate down to a dose below 125 μg, an alternative   36390/0238. Legal category: POM. NHS Cost 25 μg/125 μg 1x 120 dose MDI £14.99 and 25 μg/250
                                                                                Reporting forms and information can be found        fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the   μg 1x 120 doses MDI £19.99. Date of last revision: April 2020.
                                                                                                                                    inhaled corticosteroid is required. Use of a spacer device; where required in those with difficulties in
                                                                                     at https://yellowcard.mhra.gov.uk              coordinating actuation of the inhaler with inspiration of breath, it is recommended ONLY for higher   Adverse events should be reported. Reporting forms and  information can
                                                                                                                                    strength Sereflo containing salmeterol 25 μg and fluticasone propionate 250 μg. Patients should
                                                                                                                                    continue to use the same make of spacer device (Volumatic or the AeroChamber Plus) as switching   be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard
                                                                                                                                    between spacer devices can result in changes in the dose delivered to the lungs. See the SmPC
                                                                                 Adverse events should also be reported to          for further information on initiation, titration down and spacer use. CONTRAINDICATIONS:   in the Google Play or Apple App Store. Adverse events should also be
                                                                                     Accord-UK LTD on 01271 385257                  Hypersensitivity to the active substances or to any of the excipients. SPECIAL WARNINGS AND   reported Cipla (EU) Ltd on  0800 0472144, drugsafety@cipla.com
                                                                                                                                    PRECAUTIONS: Sereflo should not be used to treat acute asthma symptoms for which a fast- and
                                                                                  or email medinfo@accord-healthcare.com            short-acting bronchodilator is required. Patients should be advised to have their inhaler to be used
                                                                                                                                    for relief in an acute asthma attack available at all times. Patients should not be initiated on Sereflo   References.
                                                                                                                                    during an exacerbation, or significantly worsening or acutely deteriorating asthma. Serious asthma-  1. Dictionary of medicines and devices (dm+d), available at https://www.nhsbsa.nhs.uk/pharmacies-gp-
                                                                                                                                    related adverse events and exacerbations may occur with Sereflo. Patients should be asked to     practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd (accessed August 2022).
                                                                                                                                    continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen   2.  British National Formulary, Medicinal forms, available at
                                                                                                                                    after initiation. Treatment should not be stopped abruptly due to risk of exacerbation. Therapy should     https://bnf.nice.org.uk/medicinal-forms/fluticasone-with-salmeterol.html (accessed August 2022).
                                                                                                                                    be down-titrated under physician supervision. All inhaled medication containing corticosteroids   3.  MIMS.co.uk (accessed August 2022).
             Document Number:  UK-Gen-Vare-01410                                                                                    should be administered with caution in patients with active or quiescent pulmonary tuberculosis and   4. Sereflo 25 microgram/125 microgram. Summary of Product Characteristics.
                                                                                                                                                                                            5. Sereflo 25 microgram/250 microgram. Summary of Product Characteristics.
                                                                                                                                    fungal, viral or other infections of the airway. Salmeterol and fluticasone propionate should be used
             Date of Preparation: January 2025                                                                                      August 2022   CIPSER20220021
              8      PS Magazine | MDS Terms Information                                   Buy direct online at PSUK.co.uk
         P4304.1-V108_PS Magazine - Apr 25.indd   8                                                              14/03/2025   16:23:06
                                                                                                                 14/03/2025   16:23:06
         P4304.1-V108_PS Magazine - Apr 25.indd   8
   3   4   5   6   7   8   9   10   11   12   13